Comparing Enlivex Therapeutics (NASDAQ:ENLV) & Bright Minds Biosciences (NASDAQ:DRUG)

Bright Minds Biosciences (NASDAQ:DRUG) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Valuation & Earnings

This table compares Bright Minds Biosciences and Enlivex Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$2.06 million	($0.50)	-73.56
Enlivex Therapeutics	N/A	N/A	-$29.07 million	($0.98)	-1.15

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Bright Minds Biosciences and Enlivex Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0	0	3	1	3.25
Enlivex Therapeutics	0	0	2	1	3.33

Bright Minds Biosciences currently has a consensus price target of $80.00, indicating a potential upside of 117.51%. Enlivex Therapeutics has a consensus price target of $9.50, indicating a potential upside of 740.71%. Given Enlivex Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Bright Minds Biosciences.

Volatility and Risk

Bright Minds Biosciences has a beta of -6.52, meaning that its share price is 752% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares Bright Minds Biosciences and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-48.03%	-43.47%
Enlivex Therapeutics	N/A	-67.57%	-58.45%

Summary

Bright Minds Biosciences beats Enlivex Therapeutics on 7 of the 11 factors compared between the two stocks.

About Bright Minds Biosciences

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.